C-IG6JAugustine Therapeutics
HDAC6 inhibition, non-hydroxamate chemotype
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-IG6J
C-IG6JC-IG6JHDAC6 inhibition, non-hydroxamate chemotype
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Augustine Therapeutics states that it is focused on discovering and developing innovative medicines for patients with Charcot-Marie-Tooth disease and other neuromuscular diseases, building on research originating at VIB and KU Leuven.
SourceAugustine Therapeutics states that it believes innovative therapies can be developed for Charcot-Marie-Tooth disease and other neuromuscular and neurodegenerative diseases, building on pioneering research from VIB and KU Leuven and translating that work from lab to clinic to benefit patients and families affected by these conditions.
SourceAugustine Therapeutics states that it focuses on discovering and developing innovative medicines for patients with Charcot-Marie-Tooth disease and other neuromuscular diseases, presenting itself as a company built on research from VIB and KU Leuven and oriented toward therapeutic benefit for these patient groups.
SourceAugustine Therapeutics states that severe peripheral nerve disorders such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy can be addressed by advancing the science of axonal protection, regeneration, and remyelination into therapies that restore nerve function. The company says it is developing novel therapeutics aimed at achieving reinnervation, with the goal of slowing or even reversing disease and providing meaningful relief for patients with axonopathies and potentially other complex neurological disorders.
Source